rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Baxter International Inc.

BAX · NYSE

Health CareMedical DevicesLeading

BAX stood above a rising 150-day average in 17 of the last 52 weekly readings, including each of the last 17 weeks. It is 17.7% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
17 in a row
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
104

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 17 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

104 disclosed lines: House 50, Senate 52, executive 2; 23 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k23 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$50k–$100k17 Apr 2026filed 1 Jul 2026
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k31 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k30 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k30 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k25 Sep 2025filed 23 Oct 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k25 Sep 2025filed 22 Oct 2025
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k4 Aug 2025filed 12 Sep 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k22 Jul 2025filed 13 Aug 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08bought$1k–$15k15 May 2025filed 9 Jun 2025
Debbie Wasserman Schultz House: U.S. House ClerkFL25boughtdependent child$1k–$15k18 Nov 2024filed 20 Nov 2024
Earl Blumenauer House: U.S. House ClerkOR03boughtspouse$15k–$50k9 Jul 2024filed 6 Aug 2024

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Andrew P. Hider Company insiderPresident and CEO · last 2 Sep 20260 · 0
Julie Foster Company insiderPresident, Front Line Care · last 2 Sep 20260 · 0
James Teaff Company insiderPresident, CCS · last 1 Sep 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 23 Jul 20261 · 1
Steven P. Wallace Company insiderPresident, Adv. Surgery · last 2 Jun 20260 · 0
Anita A. Zielinski Company insiderSVP, Interim CFO, CAO & Cntrlr · last 1 Jun 20260 · 0
Amy McBride Wendell Company insiderDirector · last 5 May 20260 · 0
David Brent Shafer Company insiderDirector, Other · last 5 May 20260 · 0
David S. Wilkes Company insiderDirector · last 5 May 20260 · 0
Jeffrey A. Craig Company insiderDirector · last 5 May 20260 · 0
Michael R. McDonnell Company insiderDirector · last 5 May 20260 · 0
Nancy M. Schlichting Company insiderDirector · last 5 May 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202530.1%
Operating profit marginFY 2025 · to 31 Dec 2025-2.7%
Free cash flow marginFY 2025 · to 31 Dec 20253.0%
Return on capital employedFY 2025 · to 31 Dec 2025-1.8%
Debt to equityFY 2025 · to 31 Dec 20251.54×
Interest coverFY 2025 · to 31 Dec 2025-1.06×
Research spendFY 2025 · to 31 Dec 20254.6%
Share count trendFY 2025 · to 5 Feb 20260.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.0B
Free cash flowFY 2025 · to 31 Dec 2025$332.0M

Analyst forecasts

No analyst forecasts yet.